"Estradiol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
| Descriptor ID |
D004958
|
| MeSH Number(s) |
D04.210.500.365.415.248 D06.472.334.851.437.500
|
| Concept/Terms |
Estradiol- Estradiol
- Estradiol-17 beta
- Estradiol 17 beta
- Estradiol Anhydrous
- Oestradiol
- Estradiol-17beta
- Estradiol 17beta
- 17 beta-Estradiol
- 17 beta Estradiol
- 17 beta-Oestradiol
- 17 beta Oestradiol
|
Below are MeSH descriptors whose meaning is more general than "Estradiol".
Below are MeSH descriptors whose meaning is more specific than "Estradiol".
This graph shows the total number of publications written about "Estradiol" by people in this website by year, and whether "Estradiol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 1 | 2 | 3 |
| 1996 | 0 | 5 | 5 |
| 1997 | 2 | 2 | 4 |
| 1998 | 3 | 2 | 5 |
| 1999 | 3 | 2 | 5 |
| 2000 | 5 | 6 | 11 |
| 2001 | 1 | 2 | 3 |
| 2002 | 2 | 3 | 5 |
| 2003 | 7 | 1 | 8 |
| 2004 | 0 | 3 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 4 | 2 | 6 |
| 2007 | 2 | 5 | 7 |
| 2008 | 2 | 3 | 5 |
| 2009 | 5 | 4 | 9 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 3 | 4 |
| 2013 | 2 | 4 | 6 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 2 | 4 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Estradiol" by people in Profiles.
-
Early modulation of the gut microbiome by female sex hormones alters amyloid pathology and microglial function. Sci Rep. 2024 01 21; 14(1):1827.
-
Impaired inhibition after delta-9-tetrahydrocannabinol in women not related to circulating estradiol levels. Pharmacol Biochem Behav. 2023 04; 225:173547.
-
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
-
An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
-
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
-
Molecular Effects of Topical Estrogen on Vaginal Granulation Tissue in Postpartum Women. Female Pelvic Med Reconstr Surg. 2021 08 01; 27(8):521-526.
-
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
-
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
-
The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37.